Senti Biosciences, Inc. (SNTI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.93 |
| Open | 0.95 |
| Day High | 0.98 |
| Day Low | 0.95 |
| 52-Week High | 3.03 |
| 52-Week Low | 0.77 |
| Volume | 111,548 |
| Average Volume | 186,339 |
| Market Cap | 25M |
| PE | -0.65 |
| EPS | -1.46 |
| Moving Average 50 Days | 0.98 |
| Moving Average 200 Days | 1.27 |
| Change | 0.02 |
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 2:05 PM GMT
SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platf
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 2:15 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platfo
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
GlobeNewswire Inc.
Feb 20, 2026 1:50 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platfo